FEATURES OF TREATMENT OF RECURRENCE OF URATE NEPHROLITHIASIS


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Several reasons for the formation of kidney stones have been established. Recommendations for identification and elimination of established risk factors for nephrolithiasis have been developed. In patients with urate nephrolithiasis, therapy aimed at dissolving of kidney stones is very promising. Blemaren is the most popular and well-known drug for the treatment of nephrolithiasis. He has several indications for the use, including dissolution of kidney stones consisting of salts of uric acid and prevention of their recurrent formation, dissolution of kidney stones consisting of calcium oxalate. Urinary tract infections in patients with nephrolithiasis belong to the group of complicated infections. This is due to the fact that stones of the urinary tract can not only violate the outflow of urine, but are also a favorable place for fixation and preservation of the pathogens. The choice of a drug for the treatment of urinary tract infections in patients with nephrolithiasis is determined by the spectrum of possible pathogens, and also should be based on the data on the resistance of pathogens. The use of medicines containing herbal ingredients, including concentrated concentrated extracts of a mixture of grasses of the goldenrod, bottelbrush, door-weed, the roots of wheatgrass, the onion shells and birch leaves, fenugreek seeds, parsley root and lovage is discussed. Indications for the use of phytotherapy are inflammatory processes in the urinary tract and urolithiasis.

Texto integral

Acesso é fechado

Sobre autores

Petr GLYBOCHKO

MD, professor, rector of I.M. Sechenov First Moscow State Medical University. 119991, Moscow, 24 B. Pirogovskaya St

Vagarshak GRIGORYAN

MD, professor, Urological clinic, I.M. Sechenov First Moscow State Medical University 119991, Moscow, 24 B. Pirogovskaya St

Vadim RUDENKO

MD, professor, Urological clinic, I.M. Sechenov First Moscow State Medical University. 119991, Moscow, 24 B. Pirogovskaya St

Yuri DEMIDKO

Email: demidko1@mail.ru
PhD, Urological clinic, I.M. Sechenov First Moscow State Medical University. 119991, Moscow, 24 B. Pirogovskaya St

Liliya DEMIDKO

postgraduate student of the Department of urology, I.M. Sechenov First Moscow State Medical University 119991, Moscow, 24 B. Pirogovskaya St

Bibliografia

  1. Beck E.M., Riehle R.A. Jr. The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J. Urol. 1991;145(1):6-9.
  2. Butz M. Alkalizitrat-Therapie bei rezidiverender Kalzium. Urolithiasis. Urologe (B). 1987;27:95.
  3. Butz M. Zitrat und Kalziumurolithiasis, perimed Fachbuch Verl.-Ges. Erlangen, 1989.
  4. Carson C., Naber K.G. 2004. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Drugs. 2004;64(12):1359-73.
  5. Cicerello E., Merlo F., Gambaro G., Maccatrozzo L., Fandella A., Baggio B., Anselmo G. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extrcorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J. Urol. 1994;151:5-9.
  6. Dobardzic A.M., Dobardzic R. Epidemiological features of complicated UTI in a district hospital of Kuwait. Eur. J. Epidemiol. 1997;13(4):465-70.
  7. Dulce H.G., Dulce M., Butz M. Einflus von Saure- und Basenbelastung auf die Harnzusammensetzung und Loslichkeitsverhaltnisse. Fortschr. Urol. Nephrol. 1985;23:381.
  8. Emori T.G., Gaynes R.P. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 1993;6(4):428-42.
  9. Ettinger B., Par C.Y., Citron J.T., Thomas C., Adamas-Huet B., Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. 1997;158:2069-73.
  10. Griffith D.P., Osborne C.A. Infection (urease) stones. Miner Electrolyte Metab. 1987;13(4):278-85.
  11. Maisonneuvel N., Horrent S., Azar R., Odou. 1st International consultation on stone disease. Paris, 3-4 July 2001. Book of abstracts. № 10. p. 10.
  12. Moe O.W., Pearle M.S., Sakhaee K. Pharmacotherapy of urolithiasis: evidence from clinical trials. Kidney Int. 2011;79(4):385-92.
  13. Nicolle L.E. A practical guide to the management of complicated urinary tract infection. Drugs. 1997;53(4):583-92.
  14. Parsons C.L., Stauffer C., Mulholland S.G., Griffith D.P. Effect of ammonium on bacterial adherence to bladder transitional epithelium. J. Urol. 1984;132(2):365-6.
  15. Poulsen P.B., Osther P.J., Hansen B.J., Smerud K.T. 1st International Consultation on Stone Disease. Paris, 3-4 July 2001. Book of abstracts. № 31. p. 31.
  16. Rubin R.H., Shapiro E.D., Andriole V.T., Davis R.J., Stamm W.E. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 1992;15 (Suppl. 1):S216-27.
  17. Soygur T., Akbay A., Kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J. Endourol. 2002;16(3):149-5.
  18. Tiselius H.G., Ackermann D., Alken P., Buck C., Conort P., Gallucci M. 2002. Guidelines on urolithiasis. EAU, 2002.
  19. Türk C., Knoll T., Petrik A., Sarica K., Straub M., Seitz C. EAU Guidelines on diagnosis and conservative management of urolithiasis. 2011.
  20. Глыбочко П.В., Аляев Ю.Г. Урология. М.: ГЭОТАР-Медиа, 2014. 148 с. [Glybochko P.V., Alyaev Yu.G. Urology. Moscow: GEOTAR-Media, 2014. 148 p. (in Russ.)]
  21. Дзюрак В.С., Савчук В.И., Желтовская Н.И., Черненко В.В., Козарин Е.И. Использование цитратной смеси Блемарен в лечении и профилактике кальций-оксалатного нефролитиаза. Урологія. 2001;3:65-70. [Dzyurak V.S., Savchuk V.I., Zheltovskaya N.I., Chernenko V.V., Kozarin Ye.I. Use of citrate mixture Blemaren in the treatment and prevention of calcium oxalate nephrolithiasis. Urology. 2001;3:65-70 (in Ukr.)]
  22. Сергиенко Н.Ф., Шаплыгин Л.В., Кучиц С.Ф. Цитратная терапия в лечении уратного нефролитиаза. Урология и нефрология. 1999;2:34-6. [Sergienko N.F., Shaplygin L.V., Kuchits S.F. Citrate therapy in the treatment of urate nephrolithiasis. Urol. Nephrol. 1999;2:34-6 (in Russ.)]

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies